-
Kenya's economy faces climate change risks: World Bank
-
European bank battle heats up as UniCredit swoops for Commerzbank
-
Italian bank UniCredit makes bid for Germany's Commerzbank
-
AI to drive growth despite geopolitics, Taiwan's Foxconn says
-
Filipinas seek abortions online in largely Catholic nation
-
'One Battle After Another' wins best picture Oscar
-
South Koreans bask in Oscars triumph for 'KPop Demon Hunters'
-
'One Battle After Another' dominates Oscars
-
Norway's Oscar winner 'Sentimental Value': a failing father seeks redemption
-
Indonesia firms in palm oil fraud probe supplied fuel majors
-
Milan-Cortina Paralympics end as a 'beacon of unity'
-
It's 'Sinners' vs 'One Battle' as Oscars day arrives
-
Oscars night: latest developments
-
US Fed expected to hold rates steady as Iran war roils outlook
-
It's 'Sinners' v 'One Battle' as Oscars day arrives
-
US mayors push back against data center boom as AI backlash grows
-
Who covers AI business blunders? Some insurers cautiously step up
-
Election campaign deepens Congo's generational divide
-
Courchevel super-G cancelled due to snow and fog
-
Middle East turmoil revives Norway push for Arctic drilling
-
Iran, US threaten attacks on oil facilities
-
Oscars: the 10 nominees for best picture
-
Spielberg defends ballet, opera after Chalamet snub
-
Kharg Island bombed, Trump says US to escort ships through Hormuz soon
-
Jurors mull evidence in social media addiction trial
-
UK govt warns petrol retailers against 'unfair practices' during Iran war
-
Mideast war cuts Hormuz strait transit to 77 ships: maritime data firm
-
How will US oil sanctions waiver help Russia?
-
Oil stays above $100, stocks slide tracking Mideast war
-
How Iranians are communicating through internet blackout
-
Global shipping industry caught in storm of war
-
Why is the dollar profiting from Middle East war?
-
Oil dips under $100, stocks back in green tracking Mideast war
-
US Fed's preferred inflation gauge edges down
-
Deadly blast rocks Iran as leaders attend rally in show of defiance
-
Moscow pushes US to ease more oil sanctions
-
AI agent 'lobster fever' grips China despite risks
-
Thousands of Chinese boats mass at sea, raising questions
-
Casting directors finally get their due at Oscars
-
Fantastic Mr Stowaway: fox sails from Britain to New York port
-
US jury to begin deliberations in social media addiction trial
-
NASA says 'on track' for Artemis 2 launch as soon as April 1
-
Valentino mixes 80s and Baroque splendour on Rome return
-
Dating app Tinder dabbles with AI matchmaking
-
Scavenging ravens memorize vast tracts of wolf hunting grounds: study
-
Top US, China economy officials to meet for talks in Paris
-
Chile's Smiljan Radic Clarke wins Pritzker architecture prize
-
Lufthansa flights axed as pilots walk out
-
Oil tops $100 as fresh Iran attacks offset stockpiles release
-
US military 'not ready' to escort tankers through Hormuz Strait: energy secretary
What is microRNA? Nobel-winning discovery explained
The Nobel Prize in Medicine was awarded on Monday to two US scientists for discovering microRNA, a previously unknown type of genetic switch which is hoped can pave the way for new medical breakthroughs.
But while several treatments and tests are under development using microRNAs against cancer, heart disease, viruses and other illnesses, none have actually yet reached patients.
And the world paid little attention when the new Nobel laureates Victor Ambros and Gary Ruvkun revealed their discovery decades ago, thinking it was just "something weird about worms", Cambridge University geneticist Eric Miska told AFP.
Here is an explainer about how exactly these tiny genetic switches work inside our bodies.
- What is microRNA? -
Each cell in the human body has the same set of instructions, called DNA. Some turn into brain cells, while others become muscles.
So how do the cells know what to become? The relevant part of the DNA's instructions is pointed to via a process called gene regulation.
Ribonucleic acid (RNA) normally serves as a messenger. It delivers the instructions from the DNA to proteins, which are the building blocks of life that turn cells into brains -- or muscles.
Miska gave the example of the messenger RNA vaccines rolled out against Covid-19 during the pandemic, which insert a message with new instructions to build proteins that block viruses.
But the two new Nobel winners Ambros and Ruvkun discovered a whole new type of gene regulator that had previously been overlooked by science.
Rather than being the messenger which relays information, microRNA instead acts as a switch to turn other genes off and on.
"This was a whole new level of control that we had totally missed," said Miska, who has worked on microRNA for two decades, including with the new Nobel laureates.
"The discovery of microRNAs brought an additional level of complexity by revealing that regions that were thought to be non-coding play a role in gene regulation," French researcher Benoit Ballester told AFP.
- What did the Nobel winners do? -
Back in the 1980s, Ambros and Ruvkun had been working separately on how genes interact in one-millimetre-long roundworms called C.elegans.
When they compared their work, it led to the discovery of microRNA. Ambros revealed the finding in a 1993 paper.
"Nobody really paid much attention," Miska said, explaining that most scientists at the time thought it only applied to worms.
Then in 2000, Ruvkun published research showing that microRNA is present right across the animal kingdom, including in humans and even some viruses.
"This was not just something weird that worms do, but in fact all animals and plants are totally dependent for development and normal function on them," Miska said.
More than a thousand genes that respond to microRNAs are now believed to be in the human body.
- How could this help us? -
There are numerous new treatments and tests using microRNA that are undergoing trials but none have been made widely available.
"Though there are no very clear applications available yet in microRNAs, understanding them, knowing that they exist, understanding their counter-regulatory networks, is always the first step," the Karolinska Institute's Gunilla Karlsson Hedestam told journalists in Stockholm.
MicroRNAs are particularly promising for fighting cancer because some of these switches "act as a tumour suppressor, so they put a brake on cells dividing inappropriately," Miska said.
Others, meanwhile, induce "cells to divide, which can lead to cancer", he added.
Because many viruses use microRNAs, several antiviral drugs are at varying stages of development, including for hepatitis C.
One complicating factor has been that microRNAs can be unstable.
But scientists also hope they can be used as a test called a "biomarker", which could reveal what type of cancer a patient could be suffering from, for example.
- What next? -
It also appears probable that microRNAs could be involved in the evolution of our species, Miska said.
While human brains are difficult to study, Miska hoped future research will discover more.
H.Cho--CPN